

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CLSA Premium Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6877)**

### **QUARTERLY UPDATE ON PROGRESS OF RESUMPTION**

This announcement is made by CLSA Premium Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 and 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the Company’s announcements dated (i) 13 April 2023 in relation to the decision of the Listing Committee of the Stock Exchange; (ii) 25 April 2023 in relation to the suspension of trading in the Company’s shares; (iii) 17 May 2023 in relation to the resumption guidance for the Company as set out in a letter from the Stock Exchange (the “**Resumption Guidance Announcement**”); and (iv) 24 July 2023 in relation to the quarterly update on progress of resumption (the “**First Quarterly Update Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as in the First Quarterly Update Announcement.

### **UPDATE ON BUSINESS OPERATIONS OF THE GROUP**

Following the suspension of trading in the Company’s shares on the Stock Exchange on 25 April 2023, the Board has announced updates on the Group’s business on 12 May and 24 July 2023. For details, please refer to the said announcement.

In order to expand the Group’s original equipment manufacturing business, the Group had entered into a strategic cooperation agreement with Beijing Tong Ren Tang (Hong Kong) Limited (“**TRT International**”) and 中科分子生物(广东)股份有限公司 (CasMo Bio-tech (Guangdong) Co., Ltd.\*, “**CBC**”) in which (a) TRT International agreed to provide the right to use the trademark and serves as the product supervisor to develop products; (b) the Group, as the owner of the products, agreed to (i) develop the products with TRT International and CBC; (ii) take responsibility of the design and procure materials for the products packaging; and (iii) serve as the global distributor; and (c) as the products manufacturer, CBC agreed to provide technical advice on products development and production in China and overseas regions.

Based on the unaudited consolidated management accounts of the Group for the nine months ended 30 September 2023, the unaudited revenue exceeded HK\$160 million and the unaudited net profit exceeded HK\$7 million. The growth was mainly attributable to the continuous growth of the healthcare business in the second half of 2023.

To the best knowledge of the Board, as at the date of this announcement, the suspension of trading in the Company’s shares has not resulted in any significant adverse impact on the business operations of the Group in any material respect and the Group continues to carry on with its normal day-to-day operations. The Board remains fully committed to the Company and will continuously assess the impact on the business operations and financial position of the Group, take appropriate measures and make further announcement(s) as and when appropriate. The Group’s management continues to strategically review the Group’s structure, its existing businesses and potential business opportunities from time to time with the intention of improving the business operations and financial position of the Group and complying with Rule 13.24 of the Listing Rules.

## **UPDATE ON THE RESUMPTION PLAN OF THE COMPANY**

As disclosed in the Resumption Guidance Announcement, the Stock Exchange has set out the Resumption Guidance for the Company, including:

- (i) demonstrate its compliance with Rule 13.24; and
- (ii) inform the market of all material information for the Shareholders and investors to appraise the Company’s position.

\* *For identification purpose only*

The Stock Exchange required the Company to meet all Resumption Guidance, remedy the substantive issues causing its trading suspension, and fully comply with the Listing Rules to the Stock Exchange's satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has the primary responsibility to devise its action plan for resumption. Whilst the Company may seek guidance from the Stock Exchange on its resumption plan, its resumption plan is not subject to the Stock Exchange's prior approval before implementation. The Stock Exchange also indicated that it may modify or supplement the Resumption Guidance if the Company's situation changes. Under Rule 6.01A(1) of the Listing Rules, the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period expires on 24 October 2024. If the Company fails to remedy the substantive issues causing its trading suspension, fulfil the Resumption Guidance and fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in its shares by 24 October 2024, the Listing Division will recommend the Listing Committee to proceed with the cancellation of the Company's listing. Under Rules 6.01 of the Listing Rules, the Stock Exchange also has the right to impose a shorter specific remedial period, where appropriate.

The Company has been and is taking appropriate steps to resolve the issues causing its trading suspension and, in light of the complexity of the issues and amount of resources involved, has been in discussions with professional advisers to explore and consider opportunities and options available to the Company in formulating a viable resumption plan to resolve the issues leading to the trading suspension and to address the matters set out in the Resumption Guidance. The Company remains committed to using its best endeavors to satisfy the Resumption Guidance and to comply with Rule 13.24 of the Listing Rules in a manner satisfactory to the Stock Exchange as soon as practicable and will make further announcement(s) as and when appropriate should there be any material development.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Company's shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on Tuesday, 25 April 2023 and will remain suspended pending fulfilment of the Resumption Guidance and any supplement or modification thereto. Further announcement(s) will be made by the Company as and when appropriate and in compliance with the requirements under the Listing Rules.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares and/or securities of the Company.**

By Order of the Board  
**CLSA Premium Limited**  
**Yuan Feng**  
*Executive Director*

Hong Kong, 24 October 2023

*As at the date of this announcement, the Directors are:*

**Executive Directors**

Mr. Yuan Feng (*Deputy Chief Executive Officer*)

Mr. Chung Cheuk Fan Marco

**Non-executive Directors**

Mr. Li Jiong (*Chairman*)

Mr. Xu Jianqiang

**Independent non-executive Directors**

Mr. Wu Jianfeng

Ms. Hu Zhaoxia

Mr. Ma Xufei